Chest
Volume 124, Issue 4, October 2003, Pages 1224-1231
Journal home page for Chest

Clinical Investigations
A Longitudinal Study of Lung Function in Nonsmoking Patients With Rheumatoid Arthritis

https://doi.org/10.1378/chest.124.4.1224Get rights and content

Study objectives

Patients with rheumatoid arthritis (RA) have a high prevalence of pulmonary function test (PFT) abnormality, but the long-term significance of this is unknown. We performed a longitudinal study of pulmonary function in asymptomatic, nonsmoking patients with active RA requiring disease-modifying drugs. We looked for temporal change in lung function and characteristics that would predict subsequent development of PFT abnormality or respiratory symptoms.

Methods

In 1990, 52 patients (44 women; age range, 29 to 78 years; median, 56 years) underwent clinical assessment (drug history, RA severity, immunologic, and inflammatory markers) and PFTs (spirometry, body plethysmography, gas transfer). PFT results were expressed as standardized residuals (SRs). Thirty-eight patients were reassessed in 2000. A self-administered questionnaire was used to identify respiratory symptoms.

Results

The prevalence of pulmonary function abnormality was higher than expected compared with a reference population, but there was no significant increase in number over 10 years (8.7% in 1990 and 8.8% in 2000). When assessed by group means and compared with reference values, reduced diffusing capacity of the lung for carbon monoxide (Dlco) and increased ratio of residual volume (RV) to total lung capacity (TLC) [RV/TLC] were the only abnormalities to develop over the study period (mean Dlco in 2000, − 0.47 SR; 95% confidence interval [CI], – 0.91 to – 0.01; RV/TLC, 0.49 SR; 95% CI, 0.13 to 0.84). However, rates of change of pulmonary function variables were not significantly different from zero. Logistic regression did not identify any meaningful relationship between disease characteristics and PFT abnormality.

Conclusions

Asymptomatic patients with RA have a higher prevalence of PFT abnormality than expected, but these do not increase in number over time. We did not identify any patient or disease-specific characteristic that could predict the development of respiratory disease in patients with RA. Analysis using percentage of predicted values, rather than SRs, is misleading as it exaggerates the extent of abnormality present. Abnormal lung function is a common and probably benign finding in nonsmoking, asymptomatic patients with RA.

Section snippets

Recruitment

In 1990, we recruited patients from the RA second-line medication clinic at the Centre for Rheumatic Diseases at Glasgow Royal Infirmary. All patients had RA diagnosed by a consultant rheumatologist, according to American College of Rheumatology criteria,11and were receiving one or more disease-modifying antirheumatoid drugs (DMARDs). Inclusion criteria were lifelong nonsmoking, no documented or recalled evidence of lung disease, and absence of respiratory symptoms on general inquiry at initial

Results

We studied 52 patients (44 women; age range, 29 to 78 years; median, 56 years). Thirty-eight patients were seropositive, and all were receiving DMARD therapy with a median lifetime use of two agents (range, one to four agents). The DMARDs used and the number of patients prescribed them are as follows: IM gold (n = 25), sulfasalazine (n = 22), penicillamine (n = 11), hydroxychloroquine (n = 8), methotrexate (n = 4), and azathioprine (n = 3). Only three patients had been solely administered

Discussion

There have been a considerable number of cross-sectional studies looking at the prevalence of pulmonary abnormalities in patients with RA who were not known to have lung involvement. The older studies451718192021222324used PFTs to detect the abnormalities, whereas in more recent times this has been combined with HRCT of the thorax6725262728; all studies concur in that a high prevalence of abnormality (35 to 65%) can be found. By contrast, 27% of our population had pulmonary function

Conclusions

We have demonstrated that, within a population of patients with RA selected as lifelong nonsmokers with no respiratory symptoms, the prevalence of pulmonary function abnormality is higher than expected when compared with a reference population, but did not increase over 10 years. Assessed by group means and SRs, both Dlco and RV/TLC became significantly abnormal in 2000 when compared with reference values. However, rates of change of pulmonary function variables were not significantly different

References (35)

  • M Linstow et al.

    An 8-year follow-up study of pulmonary function in patients with rheumatoid arthritis

    Rheumatol Int

    (1994)
  • K Chakravarty et al.

    A longitudinal study of pulmonary function in patients with rheumatoid arthritis treated with gold and D-penicillamine

    Br J Rheumatol

    (1992)
  • FC Arnett et al.

    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

    Arthritis Rheum

    (1988)
  • DM Ritchie et al.

    Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis

    Q J Med

    (1968)
  • BG Ferris

    Epidemiology Standardization Project (American Thoracic Society)

    Am Rev Respir Dis

    (1978)
  • National Center for Health Statistics

    Third National Health and Nutrition Examination Survey, 1988–1994, NHANES III laboratory data file

    (1996)
  • Guidelines for the measurement of respiratory function. Recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists

    Respir Med

    (1994)
  • Cited by (28)

    • Predictors of airway and parenchymal lung abnormalities in patients with rheumatoid arthritis

      2021, Egyptian Rheumatologist
      Citation Excerpt :

      Pulmonary function test (PFT) abnormality has been reported in RA patients especially seropositive cases and are more likely to have obstructive and restrictive abnormalities [7]. However, most abnormalities remain clinically insignificant and asymptomatic patients with PFT abnormalities generally do not show physiologic progression over 10 years [8]. High-resolution computed tomography (HRCT) of the chest forms the basis of investigation [9].

    • Complex obstructive lung disease – A diagnostic and management conundrum

      2020, Respiratory Medicine Case Reports
      Citation Excerpt :

      In a Taiwanese retrospective cohort study, the incidence of COPD in individuals with RA was found to be 1.74 fold higher than the non-RA population; however because they used a national database that did not include information regarding tobacco use, they could not assess the effect of smoking (Shen). A prospective study of 52 non-smoking patients with “active” RA (as defined by the current use of DMARD therapy) in the United Kingdom found that there was an increased prevalence of obstructive pattern found on PFTs which did not worsen over a 10-year follow-up period [7]. These individuals did demonstrate a decline in DLCO over the same time period, which may have been attributable to their RA therapy.

    • Longitudinal changes in pulmonary function and respiratory impedance of rheumatoid arthritis

      2019, Respiratory Physiology and Neurobiology
      Citation Excerpt :

      It is likely that pulmonary functions remained in a relatively stable condition during observation periods in our RA patients who were able to undergo the follow-up pulmonary function test and Zrs measurement. Similar findings were reported for a non-smoking RA cohort (Fuld et al., 2003). The Rrs of the last assessment was significantly lower than that at the baseline at all frequencies between 4 and 36 Hz (Fig. 1A).

    • FEV<inf>1</inf> over time in patients with connective tissue disease-related bronchiolitis

      2013, Respiratory Medicine
      Citation Excerpt :

      Immunomodulatory therapies are often used in attempts to halt the progressive fibrous luminal narrowing of constrictive bronchiolitis (CB) or the transmural inflammation of cellular or follicular bronchiolitis in patients with connective tissue disease- (CTD-) related bronchiolitis. Pulmonary function tests (PFTs) are an essential part of standard monitoring in patients with CTD-related bronchiolitis; however, little is known about the natural history (or the effects of immunomodulatory therapy on lung function over time) of bronchiolar disease in these patients.1–7 Data on longitudinal trends in lung function is essential for patient management decisions and for designing therapeutic trials.

    • What is the outcome of RA in 2011 and can we predict it?

      2011, Best Practice and Research: Clinical Rheumatology
      Citation Excerpt :

      About one-third of the patients had already developed RA-ILD at baseline. In another study, including a small study population of non-smoking patients with RA without a history of respiratory disorders, the prevalence of pulmonary lung function test abnormalities was higher than expected but did not change over a 10 year period [27]. In a retrospective cohort study using annual cross-sectional data collected from 1985 to 2006 from the US Veteran’s Health Administration system, an increase in RA lung disease was observed, increasing from 19 to 22 cases per 1000 over 10 years [28].

    View all citing articles on Scopus

    Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (e-mail: [email protected]).

    View full text